Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Mallinckrodt
Moodys
Dow
Baxter

Last Updated: August 11, 2022

Investigational Drug Information for BC-3781


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug BC-3781?

BC-3781 is an investigational drug.

There have been 5 clinical trials for BC-3781. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2016.

The most common disease conditions in clinical trials are Pneumonia, Bacterial, Pneumonia, and Infections. The leading clinical trial sponsors are Nabriva Therapeutics AG and [disabled in preview].

There are ten US patents protecting this investigational drug and one hundred and fifty-six international patents.

Recent Clinical Trials for BC-3781
TitleSponsorPhase
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic FibrosisNabriva Therapeutics AGPhase 1
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With PneumoniaNabriva Therapeutics AGPhase 3
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With PneumoniaNabriva Therapeutics AGPhase 3

See all BC-3781 clinical trials

Clinical Trial Summary for BC-3781

Top disease conditions for BC-3781
Top clinical trial sponsors for BC-3781

See all BC-3781 clinical trials

US Patents for BC-3781

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BC-3781 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
BC-3781 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
BC-3781 See Plans and Pricing Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) See Plans and Pricing
BC-3781 See Plans and Pricing Crystal structure of the large ribosomal subunit from S. aureus Yeda Research and Development Co. Ltd. (Rehovot, IL) See Plans and Pricing
BC-3781 See Plans and Pricing Process for preparing pleuromutilin California Institute of Technology (Pasadena, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BC-3781

Drugname Country Document Number Estimated Expiration Related US Patent
BC-3781 Australia AU2017261372 2036-05-05 See Plans and Pricing
BC-3781 Canada CA3023278 2036-05-05 See Plans and Pricing
BC-3781 China CN107847398 2036-05-05 See Plans and Pricing
BC-3781 European Patent Office EP3452003 2036-05-05 See Plans and Pricing
BC-3781 European Patent Office EP3981392 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Mallinckrodt
Moodys
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.